Targovax Reports Results of ONCOS-102 in P-l/ll Study as 1L and 2L Treatment for Malignant Pleural Mesothelioma

November 24, 2020 Auto Bot Clinical Trials, reports, results 0

Shots:

  • The exploratory P-l/ll study involves the assessment of ONCOS-102 + SoC CT (pemetrexed/cisplatin) as a 1L and 2L treatment in 31 patients with MPM
  • Result: @18mos. follow up showed that mOS (18.2mos. vs 14.2mos.) and showed broad and powerful immune activation, associated with better survival outcome. The next survival analysis is planned in H1’21
  • Targovax and Merck are currently reviewing the next steps for combining ONCOS-102 and Keytruda in MPM

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Targovax

The post Targovax Reports Results of ONCOS-102 in P-l/ll Study as 1L and 2L Treatment for Malignant Pleural Mesothelioma first appeared on PharmaShots.